I Ziv
Overview
Explore the profile of I Ziv including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
902
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Radiolabelled apoptotic probe may be a vehicle for a novel multimodality radionuclide tumour therapy
Dizdarevic S, McCready R, Turner J, Bagley M, Blower P, Schmid P, et al.
Eur J Nucl Med Mol Imaging
. 2014 Feb;
41(6):1255-6.
PMID: 24566950
No abstract available.
2.
Ziv I, Rosen E, Elyashuv O, Segal D, Simkin A
Clin Biomech (Bristol)
. 2013 Aug;
9(3):167-73.
PMID: 23916177
The stability offered by the interfragmentary lag screw with a unilateral external fixator frame was studied in both experimental and prospective clinical studies. The in-vitro stability of the fixation with...
3.
Ziv I, Shirvan A, Offen D, Barzilai A, Melamed E
Methods Mol Med
. 2011 Feb;
62:73-87.
PMID: 21318769
The causes for the highly selective loss of dopaminergic neurons in the substantia nigra pars compacta in Parkinson's disease (PD) are still unknown. However, a major advance has been recently...
4.
Djaldetti R, Ziv I, Melamed E
J Neural Transm (Vienna)
. 2002 Jul;
109(5-6):797-803.
PMID: 12111469
Deprenyl, an irreversible MAO-B inhibitor, is known to have a symptomatic effect in de novo patients with Parkinson's disease (PD). It has, however, not been studied thoroughly in patients with...
5.
Merims D, Ziv I, Sherki Y, Djaldetti R, Melamed E
Neurol Neurochir Pol
. 2002 May;
35 Suppl 3:65-8.
PMID: 12001656
Dyskinesias are the most frequent adverse effect of chronic levodopa therapy in patients with Parkinson's disease (PD). Current pharmacological treatment for this problem is unsatisfactory. Recently, there is evidence for...
6.
Han S, Szarzanowicz T, Ziv I
Clin Biomech (Bristol)
. 2001 Jun;
14(3):I.
PMID: 11415845
No abstract available.
7.
Han S, Szarzanowicz T, Ziv I
Clin Biomech (Bristol)
. 2001 Jun;
13(7):480-484.
PMID: 11415824
OBJECTIVE: Ultrasound transmission velocity (UTV) and bone mineral density (BMD) were examined as possible predictors of the bending strength of osteoporotic long bones in ovariectomized rats treated with calcium-depleted diet....
8.
Djaldetti R, Rosmarin V, Ziv I, Melamed E
Clin Neuropharmacol
. 2001 Apr;
24(2):95-8.
PMID: 11307044
To understand the delay in the clinical benefit that commonly occurs after initiation of levodopa (L-Dopa) treatment, we examined the pharmacokinetic profile of L-Dopa after the first oral dose ever...
9.
Barzilai A, Zilkha-Falb R, Daily D, Stern N, Offen D, Ziv I, et al.
J Neural Transm Suppl
. 2001 Feb;
(60):59-76.
PMID: 11205158
Parkinson's disease (PD) is a progressive neurological disorder caused by rather selective degeneration of the dopaminergic (DA) neurons in the substantia nigra. Though subject to intensive research, the etiology of...
10.
Shirvan A, Shina R, Ziv I, Melamed E, Barzilai A
Brain Res Mol Brain Res
. 2000 Nov;
83(1-2):81-93.
PMID: 11072098
Collapsin-1/Semaphorin3A (Sema3A) belongs to the secreted type III semaphorins family of axon guidance molecules with chemorepulsive activity, and is suggested to play a major role in navigating axonal networks throughout...